¤¤¥¡°·±d«OÀI¸p¡u¥þ¥Á°·±d«OÀIÃĪ«µ¹¥I¶µ¥Ø¤Î¤ä¥I¼Ð·Ç¦@¦PÀÀq·|ij¡v°w¹ï¦´ÁªvÀø¤Î«e½uªvÀø¡A³q¹L¦h¶µ·sÃįǤJ°·«Oµ¹¥I©MÂX¼Wµ¹¥I¡A¥]¬AÀù¯g·sÃĪvÀø¦´Á¨ÅÀù¡B±ß´Á©ÎÂಾ©Ê¤T³±©Ê¨ÅÀùµ¥¦hºØ¤£¦PÀù§O¡F¨u¯f·sÃÄ¡A¦pªvÀøDravet¯gÔ¸s¡A¥H¤Î¨ä¥L·sÃÄ¡A¦pªvÀø°®Å~µ¥¯e¯f¡A¦@p¦¬¸ü11¶µ·sÃĤÎ7¶µÃÄ«~ÂX¼Wµ¹¥I³W©w¡AÁ`¦@Ѻª`ÃĶO57»õ¤¸¡A¹w¦ô¶W¹L14,554¯f¤Í¨ü´f¡C
°·«O¸p¦¬¸ü¦h¶µ·sÃÄ §UÀù¤Í°§C´_µo·ÀI»P©µªø¦s¬¡´Á
°·«O¸pªí¥Ü¡A¥»¦¸·|ij¦P·N¦¬¸ü§tabemaciclib¦¨¤À·sÀùÃÄ¡A¦³®Ä°§C¦´Á
¨ÅÀù¯f¤Í30%¥H¤W´_µo·ÀI¡F¦P®É¦¬¸ü¤£¦³µLBRCA°ò¦]¬ðÅܤ§¤T³±©Ê¨ÅÀù±wªÌ§¡¥i¨Ï¥Î¤§§tsacituzumab govitecan¦¨¤À¼Ð¹vÃĪ«¡A¥i©µªø¾ãÅé¦s¬¡´Á¬ù5.4Ó¤ë¡C
¥t¬°·ÓÅU§ó¦hÀù¯g¯f¤Í¡B´î»´Àù¤Í®a®xt¾á¡A¦P·N¦¬¸üªvÀø¡uÄjº©©Ê¤j«¬B²ÓM²O¤Ú½F¡v§tpolatuzumab vedotin¦¨¤À·sÃÄ¡AÅýµLªk¨Ï¥ÎCAR-T²ÓMªvÀø¤§Àù¤Í¡A¦³¥t¤@ÓÃÄ«~¥i¿ï¥Î¡F¥t¦P·N§tdabrafenib¤Îtrametinib¦¨¤ÀÃÄ«~¨Ö¥ÎªvÀø±ß´Á«D¤p²ÓMªÍÀù¡A¾ãÅé¦s¬¡´Á¬ù18.2Ó¤ë¡F§tobinutuzumab¦¨¤ÀÃÄ«~¥Î©óªvÀø²O¤Ú²y©Ê¥Õ¦å¯f¡A¥i©µªøµL´c¤Æ¦s¬¡´Á¬ù13.2Ó¤ë¡C
¦³2¶µÀùÃĦ]¼t°Ó¦P·N°»ùÂX¼Wµ¹¥I½d³ò¡A¥]§tªvÀø§Z±_¡B¿é§ZºÞ©Î¸¡½¤Àù¤§§tbevacizumab¦¨¤ÀÃÄ«~¤ÎªvÀø¨ã¦³17p¯Ê¥¢ªºCLL¤§§tibrutinib¦¨¤ÀÃÄ«~¡C